Liver Cancer
Filter News
Found 47 articles
-
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv... -
TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases
4/20/2023
TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD ™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases.
-
RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer
3/21/2023
RayzeBio, Inc. today announced the nomination of a first-in-class novel peptide drug candidate against GPC3. As GPC3 is selectively overexpressed in hepatocellular carcinoma and not expressed in normal liver and other tissues, it has a compelling profile for targeted cancer therapy.
-
Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal
1/24/2023
Galectin Therapeutics Inc. announced that the scientific paper, “Machine Learning Liver Histology Scores Correlate With Portal Hypertension Assessments In Nonalcoholic Steatohepatitis Cirrhosis,” was published in Alimentary Pharmacology and Therapeutics, a prominent peer-reviewed gastroenterology journal.
-
Zhongchao Inc. Established SID Liver Cancer Comprehensive-Disciplinary Physician Education Platform
12/5/2022
Zhongchao Inc. today announced that after three years of preparation, the Company's MDMOOC platform has established a "Surgical-Interventional-Drug" ("SID") platform for liver cancer comprehensive-disciplinary physician education ("SID Platform"), providing physicians with knowledge and techniques in comprehensive-disciplinary comprehensive management of patients with liver cancer.
-
As the FDA cracks down on accelerated approvals, Genentech, a Roche company, voluntarily withdrew its monoclonal antibody, Tecentriq, for metastatic bladder cancer. -
Results of a Multicenter Study on Delcath's CHEMOSAT® Hepatic Delivery System Published in Cardiovascular and Interventional Radiology
8/5/2022
Delcath Systems, Inc. announced the publication of a retrospective analysis of patients who underwent a percutaneous hepatic perfusion procedure (PHP) with CHEMOSAT® at three European centers, one in the Netherlands and two in Germany, between February 2014 and December 2019.
-
CEVEC's License Partner RZNOMICS Inc. Receives Approval to Initiate Clinical Development of CAP(R) Ad Technology-Produced Gene Therapy Vector in Liver Cancer Patients
7/13/2022
South Korean Ministry of Food and Drug Safety granted IND approval for a clinical phase 1/2a trial to evaluate safety and efficacy of RZNOMICS lead gene therapy RZ001 for the treatment of primary liver cancer.
-
The American Medical Association Approves a New Category I CPT® Code for the HelioLiver™ Test
7/5/2022
Helio Genomics, and its commercial partner, Fulgent Genetics announced that the American Medical Association has issued a new Category I Current Procedural Terminology Proprietary Laboratory Analyses code for HelioLiver™, enabling a reimbursement pathway for potential increased access and broader adoption of innovative surveillance tests for liver cancer in the U.S. The code will become effective on October 1, 2022.
-
Final analysis of the Himalaya trial demonstrated safety as well as a statistically relevant 22% improvement of overall survival (OS) without exposing the patient to an increase in liver toxicity. -
Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi
4/25/2022
Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi.
-
Helio Health Announces Publication of ENCORE Data in Hepatology Communications, Demonstrating Superior Performance of HelioLiver for Early Detection of Liver Cancer
3/7/2022
Helio Health today announced that Hepatology Communications published positive results from the ENCORE study validating HelioLiver's strong clinical performance in detecting the presence of early hepatocellular carcinoma.
-
Sirtex Medical and Grand Pharmaceutical Group Limited receive NDA approval of SIR-Spheres® Y-90 resin microspheres in China from the National Medical Products Administration
2/9/2022
Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, announced with its shareholder, Grand Pharmaceutical Group Limited, that SIR-Spheres® Y-90 resin microspheres have been approved by the National Medical Products Administration for the treatment of patients with colorectal cancer liver metastases.
-
Hepion Pharmaceuticals’ Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study
1/26/2022
Hepion Pharmaceuticals, Inc. today announced the results of a nonclinical research study showing that its clinical phase drug candidate, rencofilstat (CRV431), synergistically decreased liver tumor growth and extended mouse survival when combined with an anti-PD1 antibody, an immune checkpoint inhibitor (“ICI”).
-
First Patient Dosed in Randomised Phase 2 Clinical Trial of MTL-CEBPA in Patients with Advanced Liver Cancer
1/25/2022
MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces that it has dosed the first patient in a global Phase 2 clinical trial of MTL-CEBPA in combination with second line standard of care sorafenib ) in advanced hepatocellular carcinoma.
-
AstraZeneca has been struggling to find an effective use for its anti-CTLA-4 antibody tremelimumab. It may have finally found it.
-
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
12/21/2021
Hepion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its investigational new drug (“IND”) application for CRV431, a liver-targeting, novel cyclophilin inhibitor, for the treatment of hepatocellular carcinoma (“HCC”).
-
Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
12/20/2021
Can-Fite BioPharma Ltd today announced that the last patient treated under an Open Label Extension program of its concluded Phase II study of Namodenoson in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer, meaning that all cancer lesions have cleared.
-
FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer
11/9/2021
Clinical stage drug development company Pharmaxis Ltd announced that an Investigational New Drug application for a trial of PXS-5505 in hepatocellular carcinoma patients has been cleared by the United States Food and Drug Administration.
-
ABK Biomedical Announces Enrollment Initiation of First-in-Human Clinical Study with Eye90 microspheres™ for treatment of liver tumors
11/1/2021
ABK Biomedical, Inc. announced the approval and initiation of a First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device, in collaboration with Auckland Hospital Research Unit, New Zealand.